CalicoBiosystems SA

In the next decade, cancer will kill 1 in 6 individuals. Because they are tested in
artificial models, 95% of anti-cancer drugs fail to reach approval due to a lack of
efficacy. Calico Biosystems is the only platform that tests drugs directly on
patient tumors and is therefore capable of reliably predicting drug efficacy in
patients. Further, thanks to its unique merged experimental and digital
approaches, Calico Biosystems simulates and predicts the outcome of any
combination of treatments and identifies the most potent combinations of drugs.
Calico Biosystems’ activities in the EU and USA are poised to capture 8% of a
global market valued at 250 billion USD by 2030.